Shorter infusion may be just as good for preventing repeat variceal bleeding
NCT ID NCT03624517
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether giving the drug octreotide for 24 hours instead of the usual 72 hours could prevent early rebleeding from esophageal varices in people with cirrhosis. The trial included 34 adults with active bleeding from varices who underwent endoscopic banding. The goal was to see if the shorter infusion was safe and effective, but the study was stopped early, so the findings are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
octreotide
What this could lead to
If successful, this could show that a shorter 24-hour octreotide infusion is just as safe and effective as the standard 72-hour regimen, potentially reducing hospital stay and treatment burden.
What could go wrong
The trial was terminated early with only 34 participants, so results are limited and may not be reliable. It is unclear if the shorter infusion truly prevents rebleeding as well as the longer one.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brooke Army Medical Center
Houston, Texas, 78234, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Texas Tech University Health Sciences Center
El Paso, Texas, 79905, United States
-
The Ohio state University
Columbus, Ohio, 43210, United States
-
The University of Texas at Austin
Austin, Texas, 78712, United States
-
University of Florida Health
Jacksonville, Florida, 32209, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60607, United States